nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Tamoxifen—pancreatic cancer	0.0619	0.133	CbGbCtD
Dihydroergotamine—ABCB1—Gemcitabine—pancreatic cancer	0.0533	0.115	CbGbCtD
Dihydroergotamine—ABCB1—Erlotinib—pancreatic cancer	0.0526	0.113	CbGbCtD
Dihydroergotamine—ABCB1—Irinotecan—pancreatic cancer	0.0475	0.102	CbGbCtD
Dihydroergotamine—CYP3A4—Tamoxifen—pancreatic cancer	0.0371	0.0797	CbGbCtD
Dihydroergotamine—ABCB1—Docetaxel—pancreatic cancer	0.0348	0.0749	CbGbCtD
Dihydroergotamine—ABCB1—Sunitinib—pancreatic cancer	0.0347	0.0745	CbGbCtD
Dihydroergotamine—CYP3A4—Erlotinib—pancreatic cancer	0.0315	0.0678	CbGbCtD
Dihydroergotamine—CYP3A4—Irinotecan—pancreatic cancer	0.0285	0.0612	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—pancreatic cancer	0.026	0.0558	CbGbCtD
Dihydroergotamine—CYP3A4—Docetaxel—pancreatic cancer	0.0209	0.0449	CbGbCtD
Dihydroergotamine—CYP3A4—Sunitinib—pancreatic cancer	0.0208	0.0447	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—pancreatic cancer	0.0155	0.0334	CbGbCtD
Dihydroergotamine—Hypotension—Irinotecan—pancreatic cancer	0.000565	0.00158	CcSEcCtD
Dihydroergotamine—Migraine—Epirubicin—pancreatic cancer	0.000565	0.00158	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—pancreatic cancer	0.000563	0.00157	CcSEcCtD
Dihydroergotamine—Anorexia—Gemcitabine—pancreatic cancer	0.000562	0.00157	CcSEcCtD
Dihydroergotamine—Dizziness—Erlotinib—pancreatic cancer	0.000561	0.00157	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—pancreatic cancer	0.000554	0.00155	CcSEcCtD
Dihydroergotamine—Anorexia—Fluorouracil—pancreatic cancer	0.000552	0.00154	CcSEcCtD
Dihydroergotamine—Hypotension—Gemcitabine—pancreatic cancer	0.000551	0.00154	CcSEcCtD
Dihydroergotamine—Insomnia—Irinotecan—pancreatic cancer	0.000547	0.00153	CcSEcCtD
Dihydroergotamine—Flushing—Docetaxel—pancreatic cancer	0.000546	0.00153	CcSEcCtD
Dihydroergotamine—Vomiting—Tamoxifen—pancreatic cancer	0.000545	0.00152	CcSEcCtD
Dihydroergotamine—Paraesthesia—Irinotecan—pancreatic cancer	0.000543	0.00152	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000542	0.00151	CcSEcCtD
Dihydroergotamine—Hypotension—Fluorouracil—pancreatic cancer	0.000542	0.00151	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000541	0.00151	CcSEcCtD
Dihydroergotamine—Rash—Tamoxifen—pancreatic cancer	0.000541	0.00151	CcSEcCtD
Dihydroergotamine—Dermatitis—Tamoxifen—pancreatic cancer	0.00054	0.00151	CcSEcCtD
Dihydroergotamine—Vomiting—Erlotinib—pancreatic cancer	0.00054	0.00151	CcSEcCtD
Dihydroergotamine—Dyspnoea—Irinotecan—pancreatic cancer	0.00054	0.00151	CcSEcCtD
Dihydroergotamine—Somnolence—Irinotecan—pancreatic cancer	0.000538	0.0015	CcSEcCtD
Dihydroergotamine—Headache—Tamoxifen—pancreatic cancer	0.000537	0.0015	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000537	0.0015	CcSEcCtD
Dihydroergotamine—Rash—Erlotinib—pancreatic cancer	0.000535	0.00149	CcSEcCtD
Dihydroergotamine—Dermatitis—Erlotinib—pancreatic cancer	0.000535	0.00149	CcSEcCtD
Dihydroergotamine—Insomnia—Gemcitabine—pancreatic cancer	0.000533	0.00149	CcSEcCtD
Dihydroergotamine—Dyspepsia—Irinotecan—pancreatic cancer	0.000533	0.00149	CcSEcCtD
Dihydroergotamine—Headache—Erlotinib—pancreatic cancer	0.000532	0.00149	CcSEcCtD
Dihydroergotamine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000529	0.00148	CcSEcCtD
Dihydroergotamine—Chills—Docetaxel—pancreatic cancer	0.000528	0.00148	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000528	0.00148	CcSEcCtD
Dihydroergotamine—Asthenia—Sunitinib—pancreatic cancer	0.000527	0.00147	CcSEcCtD
Dihydroergotamine—Decreased appetite—Irinotecan—pancreatic cancer	0.000526	0.00147	CcSEcCtD
Dihydroergotamine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000526	0.00147	CcSEcCtD
Dihydroergotamine—Insomnia—Fluorouracil—pancreatic cancer	0.000524	0.00146	CcSEcCtD
Dihydroergotamine—Somnolence—Gemcitabine—pancreatic cancer	0.000524	0.00146	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—pancreatic cancer	0.000523	0.00146	CcSEcCtD
Dihydroergotamine—Fatigue—Irinotecan—pancreatic cancer	0.000522	0.00146	CcSEcCtD
Dihydroergotamine—Paraesthesia—Fluorouracil—pancreatic cancer	0.00052	0.00145	CcSEcCtD
Dihydroergotamine—Pruritus—Sunitinib—pancreatic cancer	0.00052	0.00145	CcSEcCtD
Dihydroergotamine—Pain—Irinotecan—pancreatic cancer	0.000517	0.00145	CcSEcCtD
Dihydroergotamine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000517	0.00144	CcSEcCtD
Dihydroergotamine—Somnolence—Fluorouracil—pancreatic cancer	0.000515	0.00144	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—pancreatic cancer	0.000513	0.00143	CcSEcCtD
Dihydroergotamine—Decreased appetite—Gemcitabine—pancreatic cancer	0.000512	0.00143	CcSEcCtD
Dihydroergotamine—Dyspepsia—Fluorouracil—pancreatic cancer	0.00051	0.00143	CcSEcCtD
Dihydroergotamine—Nausea—Tamoxifen—pancreatic cancer	0.000509	0.00142	CcSEcCtD
Dihydroergotamine—Fatigue—Gemcitabine—pancreatic cancer	0.000508	0.00142	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—pancreatic cancer	0.000506	0.00141	CcSEcCtD
Dihydroergotamine—Pain—Gemcitabine—pancreatic cancer	0.000504	0.00141	CcSEcCtD
Dihydroergotamine—Nausea—Erlotinib—pancreatic cancer	0.000504	0.00141	CcSEcCtD
Dihydroergotamine—Decreased appetite—Fluorouracil—pancreatic cancer	0.000504	0.00141	CcSEcCtD
Dihydroergotamine—Diarrhoea—Sunitinib—pancreatic cancer	0.000503	0.0014	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000499	0.00139	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—pancreatic cancer	0.000496	0.00139	CcSEcCtD
Dihydroergotamine—Pain—Fluorouracil—pancreatic cancer	0.000496	0.00138	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000495	0.00138	CcSEcCtD
Dihydroergotamine—Muscle spasms—Docetaxel—pancreatic cancer	0.000493	0.00138	CcSEcCtD
Dihydroergotamine—Dizziness—Sunitinib—pancreatic cancer	0.000486	0.00136	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000486	0.00136	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—pancreatic cancer	0.000483	0.00135	CcSEcCtD
Dihydroergotamine—Body temperature increased—Irinotecan—pancreatic cancer	0.000478	0.00134	CcSEcCtD
Dihydroergotamine—Abdominal pain—Irinotecan—pancreatic cancer	0.000478	0.00134	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000478	0.00133	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—pancreatic cancer	0.000477	0.00133	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—pancreatic cancer	0.000468	0.00131	CcSEcCtD
Dihydroergotamine—Vomiting—Sunitinib—pancreatic cancer	0.000467	0.00131	CcSEcCtD
Dihydroergotamine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000466	0.0013	CcSEcCtD
Dihydroergotamine—Rash—Sunitinib—pancreatic cancer	0.000463	0.00129	CcSEcCtD
Dihydroergotamine—Dermatitis—Sunitinib—pancreatic cancer	0.000463	0.00129	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000461	0.00129	CcSEcCtD
Dihydroergotamine—Urticaria—Fluorouracil—pancreatic cancer	0.00046	0.00129	CcSEcCtD
Dihydroergotamine—Headache—Sunitinib—pancreatic cancer	0.00046	0.00129	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—pancreatic cancer	0.000459	0.00128	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—pancreatic cancer	0.000458	0.00128	CcSEcCtD
Dihydroergotamine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000458	0.00128	CcSEcCtD
Dihydroergotamine—Palpitations—Docetaxel—pancreatic cancer	0.000453	0.00127	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—pancreatic cancer	0.000447	0.00125	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000446	0.00125	CcSEcCtD
Dihydroergotamine—Hypertension—Docetaxel—pancreatic cancer	0.000443	0.00124	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—pancreatic cancer	0.000442	0.00123	CcSEcCtD
Dihydroergotamine—Myalgia—Docetaxel—pancreatic cancer	0.000436	0.00122	CcSEcCtD
Dihydroergotamine—Arthralgia—Docetaxel—pancreatic cancer	0.000436	0.00122	CcSEcCtD
Dihydroergotamine—Nausea—Sunitinib—pancreatic cancer	0.000436	0.00122	CcSEcCtD
Dihydroergotamine—Asthenia—Irinotecan—pancreatic cancer	0.000434	0.00121	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—pancreatic cancer	0.00043	0.0012	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000427	0.00119	CcSEcCtD
Dihydroergotamine—Dry mouth—Docetaxel—pancreatic cancer	0.000427	0.00119	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000427	0.00119	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—pancreatic cancer	0.000424	0.00118	CcSEcCtD
Dihydroergotamine—Asthenia—Gemcitabine—pancreatic cancer	0.000423	0.00118	CcSEcCtD
Dihydroergotamine—Confusional state—Docetaxel—pancreatic cancer	0.000422	0.00118	CcSEcCtD
Dihydroergotamine—Oedema—Docetaxel—pancreatic cancer	0.000418	0.00117	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—pancreatic cancer	0.000417	0.00117	CcSEcCtD
Dihydroergotamine—Pruritus—Gemcitabine—pancreatic cancer	0.000417	0.00117	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—pancreatic cancer	0.000415	0.00116	CcSEcCtD
Dihydroergotamine—Diarrhoea—Irinotecan—pancreatic cancer	0.000414	0.00116	CcSEcCtD
Dihydroergotamine—Shock—Docetaxel—pancreatic cancer	0.000412	0.00115	CcSEcCtD
Dihydroergotamine—Pruritus—Fluorouracil—pancreatic cancer	0.00041	0.00115	CcSEcCtD
Dihydroergotamine—Tachycardia—Docetaxel—pancreatic cancer	0.000408	0.00114	CcSEcCtD
Dihydroergotamine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000403	0.00113	CcSEcCtD
Dihydroergotamine—Dizziness—Irinotecan—pancreatic cancer	0.0004	0.00112	CcSEcCtD
Dihydroergotamine—Anorexia—Docetaxel—pancreatic cancer	0.000399	0.00111	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—pancreatic cancer	0.000398	0.00111	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000398	0.00111	CcSEcCtD
Dihydroergotamine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000397	0.00111	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000395	0.0011	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—pancreatic cancer	0.000394	0.0011	CcSEcCtD
Dihydroergotamine—Hypotension—Docetaxel—pancreatic cancer	0.000391	0.00109	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—pancreatic cancer	0.000386	0.00108	CcSEcCtD
Dihydroergotamine—Vomiting—Irinotecan—pancreatic cancer	0.000385	0.00107	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—pancreatic cancer	0.000384	0.00107	CcSEcCtD
Dihydroergotamine—Dizziness—Fluorouracil—pancreatic cancer	0.000383	0.00107	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—pancreatic cancer	0.000383	0.00107	CcSEcCtD
Dihydroergotamine—Rash—Irinotecan—pancreatic cancer	0.000382	0.00107	CcSEcCtD
Dihydroergotamine—Dermatitis—Irinotecan—pancreatic cancer	0.000381	0.00107	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000381	0.00106	CcSEcCtD
Dihydroergotamine—Headache—Irinotecan—pancreatic cancer	0.000379	0.00106	CcSEcCtD
Dihydroergotamine—Insomnia—Docetaxel—pancreatic cancer	0.000378	0.00106	CcSEcCtD
Dihydroergotamine—Paraesthesia—Docetaxel—pancreatic cancer	0.000376	0.00105	CcSEcCtD
Dihydroergotamine—Vomiting—Gemcitabine—pancreatic cancer	0.000375	0.00105	CcSEcCtD
Dihydroergotamine—Dyspnoea—Docetaxel—pancreatic cancer	0.000373	0.00104	CcSEcCtD
Dihydroergotamine—Somnolence—Docetaxel—pancreatic cancer	0.000372	0.00104	CcSEcCtD
Dihydroergotamine—Rash—Gemcitabine—pancreatic cancer	0.000372	0.00104	CcSEcCtD
Dihydroergotamine—Dermatitis—Gemcitabine—pancreatic cancer	0.000371	0.00104	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—pancreatic cancer	0.00037	0.00103	CcSEcCtD
Dihydroergotamine—Headache—Gemcitabine—pancreatic cancer	0.000369	0.00103	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—pancreatic cancer	0.000369	0.00103	CcSEcCtD
Dihydroergotamine—Vomiting—Fluorouracil—pancreatic cancer	0.000369	0.00103	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—pancreatic cancer	0.000368	0.00103	CcSEcCtD
Dihydroergotamine—Dyspepsia—Docetaxel—pancreatic cancer	0.000368	0.00103	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000366	0.00102	CcSEcCtD
Dihydroergotamine—Rash—Fluorouracil—pancreatic cancer	0.000365	0.00102	CcSEcCtD
Dihydroergotamine—Dermatitis—Fluorouracil—pancreatic cancer	0.000365	0.00102	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—pancreatic cancer	0.000365	0.00102	CcSEcCtD
Dihydroergotamine—Decreased appetite—Docetaxel—pancreatic cancer	0.000364	0.00102	CcSEcCtD
Dihydroergotamine—Headache—Fluorouracil—pancreatic cancer	0.000363	0.00101	CcSEcCtD
Dihydroergotamine—Fatigue—Docetaxel—pancreatic cancer	0.000361	0.00101	CcSEcCtD
Dihydroergotamine—Nausea—Irinotecan—pancreatic cancer	0.000359	0.001	CcSEcCtD
Dihydroergotamine—Pain—Docetaxel—pancreatic cancer	0.000358	0.000999	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—pancreatic cancer	0.000356	0.000996	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—pancreatic cancer	0.000354	0.000989	CcSEcCtD
Dihydroergotamine—Nausea—Gemcitabine—pancreatic cancer	0.00035	0.000978	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000345	0.000963	CcSEcCtD
Dihydroergotamine—Nausea—Fluorouracil—pancreatic cancer	0.000344	0.000962	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—pancreatic cancer	0.000343	0.000957	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000342	0.000956	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—pancreatic cancer	0.000341	0.000953	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—pancreatic cancer	0.000339	0.000948	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—pancreatic cancer	0.000336	0.000938	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—pancreatic cancer	0.000332	0.000929	CcSEcCtD
Dihydroergotamine—Abdominal pain—Docetaxel—pancreatic cancer	0.000331	0.000924	CcSEcCtD
Dihydroergotamine—Body temperature increased—Docetaxel—pancreatic cancer	0.000331	0.000924	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—pancreatic cancer	0.00033	0.000921	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000321	0.000896	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—pancreatic cancer	0.000318	0.000888	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—pancreatic cancer	0.000314	0.000877	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—pancreatic cancer	0.000312	0.000871	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—pancreatic cancer	0.000311	0.000868	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—pancreatic cancer	0.000311	0.000868	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000308	0.000861	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000308	0.000859	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—pancreatic cancer	0.000306	0.000854	CcSEcCtD
Dihydroergotamine—Asthenia—Docetaxel—pancreatic cancer	0.0003	0.000839	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—pancreatic cancer	0.000298	0.000834	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000297	0.000829	CcSEcCtD
Dihydroergotamine—Pruritus—Docetaxel—pancreatic cancer	0.000296	0.000827	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—pancreatic cancer	0.000294	0.000822	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—pancreatic cancer	0.000294	0.000822	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—pancreatic cancer	0.000294	0.000821	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—pancreatic cancer	0.000293	0.000819	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—pancreatic cancer	0.000291	0.000812	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—pancreatic cancer	0.000288	0.000806	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—pancreatic cancer	0.000288	0.000804	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—pancreatic cancer	0.000287	0.000803	CcSEcCtD
Dihydroergotamine—Diarrhoea—Docetaxel—pancreatic cancer	0.000286	0.0008	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—pancreatic cancer	0.000285	0.000795	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—pancreatic cancer	0.000283	0.00079	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—pancreatic cancer	0.000282	0.000788	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—pancreatic cancer	0.000278	0.000776	CcSEcCtD
Dihydroergotamine—Dizziness—Docetaxel—pancreatic cancer	0.000277	0.000773	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—pancreatic cancer	0.000276	0.000772	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—pancreatic cancer	0.000275	0.000769	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000273	0.000762	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—pancreatic cancer	0.000272	0.000761	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—pancreatic cancer	0.000272	0.000761	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—pancreatic cancer	0.000271	0.000758	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—pancreatic cancer	0.000269	0.000752	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—pancreatic cancer	0.000269	0.000751	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—pancreatic cancer	0.000266	0.000744	CcSEcCtD
Dihydroergotamine—Vomiting—Docetaxel—pancreatic cancer	0.000266	0.000743	CcSEcCtD
Dihydroergotamine—Rash—Docetaxel—pancreatic cancer	0.000264	0.000737	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—pancreatic cancer	0.000264	0.000737	CcSEcCtD
Dihydroergotamine—Dermatitis—Docetaxel—pancreatic cancer	0.000264	0.000736	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—pancreatic cancer	0.000263	0.000735	CcSEcCtD
Dihydroergotamine—Headache—Docetaxel—pancreatic cancer	0.000262	0.000732	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—pancreatic cancer	0.000261	0.000729	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000257	0.000718	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—pancreatic cancer	0.000257	0.000718	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—pancreatic cancer	0.000255	0.000713	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—pancreatic cancer	0.000255	0.000712	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—pancreatic cancer	0.000253	0.000708	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000252	0.000705	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—pancreatic cancer	0.000252	0.000703	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—pancreatic cancer	0.000251	0.000701	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—pancreatic cancer	0.000249	0.000695	CcSEcCtD
Dihydroergotamine—Nausea—Docetaxel—pancreatic cancer	0.000248	0.000694	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—pancreatic cancer	0.000248	0.000694	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—pancreatic cancer	0.000245	0.000685	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—pancreatic cancer	0.000244	0.000682	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—pancreatic cancer	0.000243	0.00068	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—pancreatic cancer	0.000241	0.000674	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000238	0.000665	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—pancreatic cancer	0.000236	0.00066	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000234	0.000655	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000233	0.00065	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000233	0.00065	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—pancreatic cancer	0.000232	0.000648	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000231	0.000645	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—pancreatic cancer	0.00023	0.000642	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—pancreatic cancer	0.000227	0.000634	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—pancreatic cancer	0.000225	0.000629	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—pancreatic cancer	0.000224	0.000626	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—pancreatic cancer	0.000223	0.000624	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—pancreatic cancer	0.000223	0.000623	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—pancreatic cancer	0.000223	0.000623	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000215	0.000601	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000213	0.000596	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000208	0.000581	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—pancreatic cancer	0.000207	0.000579	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000206	0.000577	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000206	0.000577	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—pancreatic cancer	0.000202	0.000566	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—pancreatic cancer	0.0002	0.000558	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—pancreatic cancer	0.000193	0.000539	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000192	0.000537	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—pancreatic cancer	0.000187	0.000523	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—pancreatic cancer	0.000187	0.000521	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—pancreatic cancer	0.000185	0.000516	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—pancreatic cancer	0.000179	0.000501	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000179	0.000499	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—pancreatic cancer	0.000178	0.000497	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—pancreatic cancer	0.000178	0.000497	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—pancreatic cancer	0.000177	0.000494	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—pancreatic cancer	0.000173	0.000482	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—pancreatic cancer	0.000168	0.000468	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—pancreatic cancer	0.000166	0.000464	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—pancreatic cancer	0.000165	0.00046	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—pancreatic cancer	0.000164	0.000459	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—pancreatic cancer	0.000164	0.000457	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—pancreatic cancer	0.000155	0.000433	CcSEcCtD
Dihydroergotamine—HTR1D—Signaling Pathways—EGF—pancreatic cancer	3.35e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GCG—pancreatic cancer	3.35e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CG—pancreatic cancer	3.32e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—NRAS—pancreatic cancer	3.32e-05	0.000188	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGF—pancreatic cancer	3.28e-05	0.000185	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CB—pancreatic cancer	3.28e-05	0.000185	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	3.26e-05	0.000184	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TYMS—pancreatic cancer	3.24e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NFKBIA—pancreatic cancer	3.22e-05	0.000182	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TGFB1—pancreatic cancer	3.22e-05	0.000182	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGTR1—pancreatic cancer	3.2e-05	0.000181	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOTCH1—pancreatic cancer	3.19e-05	0.00018	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCL8—pancreatic cancer	3.16e-05	0.000178	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STK11—pancreatic cancer	3.15e-05	0.000178	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CG—pancreatic cancer	3.12e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—NRAS—pancreatic cancer	3.12e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—EGFR—pancreatic cancer	3.12e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—EGFR—pancreatic cancer	3.09e-05	0.000175	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGF—pancreatic cancer	3.09e-05	0.000174	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TYMP—pancreatic cancer	3.06e-05	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—pancreatic cancer	3.03e-05	0.000171	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CD—pancreatic cancer	3.01e-05	0.00017	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TERT—pancreatic cancer	3e-05	0.00017	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—KRAS—pancreatic cancer	2.98e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CD—pancreatic cancer	2.98e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.98e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CD—pancreatic cancer	2.96e-05	0.000167	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.96e-05	0.000167	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—KRAS—pancreatic cancer	2.94e-05	0.000166	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CD—pancreatic cancer	2.92e-05	0.000165	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—KRAS—pancreatic cancer	2.92e-05	0.000165	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.89e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CD44—pancreatic cancer	2.89e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HIF1A—pancreatic cancer	2.87e-05	0.000162	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TSC2—pancreatic cancer	2.87e-05	0.000162	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—KRAS—pancreatic cancer	2.86e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—pancreatic cancer	2.84e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	2.84e-05	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—pancreatic cancer	2.81e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GCG—pancreatic cancer	2.77e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	2.76e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KDR—pancreatic cancer	2.75e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CD—pancreatic cancer	2.74e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	2.74e-05	0.000155	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	2.73e-05	0.000154	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.72e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—pancreatic cancer	2.7e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	2.7e-05	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—KRAS—pancreatic cancer	2.69e-05	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—pancreatic cancer	2.68e-05	0.000151	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—pancreatic cancer	2.65e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—pancreatic cancer	2.64e-05	0.000149	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.63e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CB—pancreatic cancer	2.62e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	2.61e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—STK11—pancreatic cancer	2.61e-05	0.000147	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CB—pancreatic cancer	2.6e-05	0.000147	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	2.59e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	2.58e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CB—pancreatic cancer	2.55e-05	0.000144	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	2.54e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	2.53e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	2.53e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—pancreatic cancer	2.52e-05	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGF—pancreatic cancer	2.5e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HRAS—pancreatic cancer	2.5e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—pancreatic cancer	2.5e-05	0.000141	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HRAS—pancreatic cancer	2.48e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	2.48e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	2.47e-05	0.000139	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.46e-05	0.000139	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—pancreatic cancer	2.45e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—pancreatic cancer	2.43e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HRAS—pancreatic cancer	2.43e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.42e-05	0.000137	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—pancreatic cancer	2.41e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—pancreatic cancer	2.41e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	2.39e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—pancreatic cancer	2.39e-05	0.000135	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	2.38e-05	0.000134	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—pancreatic cancer	2.36e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	2.36e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—pancreatic cancer	2.35e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—pancreatic cancer	2.34e-05	0.000132	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—pancreatic cancer	2.33e-05	0.000131	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CTNNB1—pancreatic cancer	2.32e-05	0.000131	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	2.31e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CTNNB1—pancreatic cancer	2.31e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.3e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	2.3e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—pancreatic cancer	2.3e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	2.28e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—pancreatic cancer	2.28e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—pancreatic cancer	2.28e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTEN—pancreatic cancer	2.26e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—pancreatic cancer	2.26e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	2.26e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CTNNB1—pancreatic cancer	2.26e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	2.25e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTEN—pancreatic cancer	2.25e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TYMS—pancreatic cancer	2.24e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	2.24e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	2.23e-05	0.000126	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	2.22e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—pancreatic cancer	2.21e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—pancreatic cancer	2.21e-05	0.000125	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	2.2e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.2e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTEN—pancreatic cancer	2.2e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	2.2e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—pancreatic cancer	2.19e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	2.18e-05	0.000123	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	2.16e-05	0.000122	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—pancreatic cancer	2.15e-05	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	2.14e-05	0.000121	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	2.12e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SRC—pancreatic cancer	2.1e-05	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	2.09e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SRC—pancreatic cancer	2.08e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	2.08e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	2.07e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	2.05e-05	0.000116	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—pancreatic cancer	2.05e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SRC—pancreatic cancer	2.04e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	2.03e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—pancreatic cancer	2.03e-05	0.000115	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—pancreatic cancer	2.03e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NRAS—pancreatic cancer	2.02e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	2.02e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—pancreatic cancer	2.01e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NRAS—pancreatic cancer	2e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	2e-05	0.000113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	1.99e-05	0.000112	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	1.99e-05	0.000112	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—pancreatic cancer	1.99e-05	0.000112	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—pancreatic cancer	1.97e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	1.97e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NRAS—pancreatic cancer	1.96e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.94e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SRC—pancreatic cancer	1.92e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MYC—pancreatic cancer	1.88e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—pancreatic cancer	1.88e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MYC—pancreatic cancer	1.87e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	1.87e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	1.86e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—pancreatic cancer	1.86e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	1.85e-05	0.000105	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	1.85e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	1.84e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—pancreatic cancer	1.84e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MYC—pancreatic cancer	1.83e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	1.83e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	1.82e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	1.82e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—pancreatic cancer	1.82e-05	0.000103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	1.81e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	1.81e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.8e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	1.79e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	1.78e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD44—pancreatic cancer	1.78e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	1.75e-05	9.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KRAS—pancreatic cancer	1.74e-05	9.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	1.74e-05	9.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.73e-05	9.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	1.73e-05	9.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.72e-05	9.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MYC—pancreatic cancer	1.72e-05	9.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	1.71e-05	9.67e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	1.71e-05	9.67e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCG—pancreatic cancer	1.71e-05	9.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	1.69e-05	9.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	1.69e-05	9.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	1.68e-05	9.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	1.68e-05	9.46e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.65e-05	9.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.64e-05	9.23e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—STK11—pancreatic cancer	1.61e-05	9.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	1.6e-05	9.02e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—pancreatic cancer	1.59e-05	8.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	1.59e-05	8.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.59e-05	8.95e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTEN—pancreatic cancer	1.58e-05	8.89e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.57e-05	8.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SRC—pancreatic cancer	1.55e-05	8.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.55e-05	8.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—pancreatic cancer	1.55e-05	8.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—pancreatic cancer	1.53e-05	8.66e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.52e-05	8.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	1.51e-05	8.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—pancreatic cancer	1.5e-05	8.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	1.5e-05	8.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	1.5e-05	8.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	1.48e-05	8.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	1.47e-05	8.28e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.47e-05	8.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.46e-05	8.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.46e-05	8.22e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.45e-05	8.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	1.44e-05	8.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.42e-05	7.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.41e-05	7.96e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.4e-05	7.92e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MYC—pancreatic cancer	1.39e-05	7.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	1.39e-05	7.84e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.38e-05	7.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.36e-05	7.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.36e-05	7.69e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.35e-05	7.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.35e-05	7.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.33e-05	7.48e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.32e-05	7.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	1.31e-05	7.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	1.3e-05	7.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	1.29e-05	7.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	1.29e-05	7.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	1.27e-05	7.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.26e-05	7.12e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.25e-05	7.05e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.22e-05	6.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	1.19e-05	6.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.19e-05	6.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.18e-05	6.68e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.18e-05	6.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.18e-05	6.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.14e-05	6.46e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—pancreatic cancer	1.12e-05	6.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.11e-05	6.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.09e-05	6.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.09e-05	6.18e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.09e-05	6.17e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTEN—pancreatic cancer	1.09e-05	6.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.07e-05	6.05e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.01e-05	5.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.01e-05	5.71e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—pancreatic cancer	9.78e-06	5.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	9.66e-06	5.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	9.29e-06	5.25e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—pancreatic cancer	9.08e-06	5.13e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	8.99e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	8.91e-06	5.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	8.6e-06	4.85e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	7.77e-06	4.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	7.7e-06	4.35e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	7.69e-06	4.34e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	7.59e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTEN—pancreatic cancer	6.71e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—pancreatic cancer	6.28e-06	3.54e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.74e-06	2.67e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.87e-06	2.18e-05	CbGpPWpGaD
